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Abstract
Objective. Adaptive designs can enable highly sophisticated and efficient early phase trials, but the clin-
ical inference from these trials is surrounded by complexity, and currently there is a paucity but steadily
increasing amount of use of these designs in all fields of medicine. We aim to review early phase trials in
RA to discover those that have used adaptive designs and benchmark trial characteristics.
Methods. From an OVID search for journal articles reporting the results of early phase trials in rheuma-
tology, 35 studies were found, with 9 subsequently excluded; 11 were added from manual searches and
19 from searching the references. Study characteristics were extracted from the 56 papers (describing 62
trials), including the number of arms, number of patients, the primary outcome and when it was measured.
Result. One early phase trial using an adaptive design was found. The benchmark early phase trial in
RA is a phase II double-blinded randomized trial, with four arms (one control and three intervention),
each with 34 patients, and ACR20 measured at 16 weeks as the primary outcome.
Conclusion. The one adaptive design reviewed here, and a simulation study found in the search,
both indicate that adaptive designs can be applied to early phase trials in RA. We have described the
benchmark, which the efficiency of early phase trials using an adaptive design needs to exceed. These
efficient designs could drive down numbers required, time for data collection and thus cost. Changes
have been suggested, but more needs to be done.
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Introduction
Randomized controlled trials are the gold standard in
evidence-based medicine. However, many clinical trials
struggle to meet the recruitment target and time line [1].
This issue is not unique to rheumatology; randomized
controlled trials are resource intensive in terms of time,
personnel, finance and the available patient pool. Some
of these obstacles might be mitigated by the use of
adaptive trial designs, which have been developed to
improve clinical trial efficiency. The application of adap-
tive designs in early phase trials has become highly
pragmatic, efficient and pertinent. Both the US Food
Key messages
. A paucity of adaptive designs is found in early stage RA trials.
. Research into RA treatments must make use of adaptive designs.
. Research into relevant, early time-point, patient-reported, RA outcome measures is required to aid these designs.
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and Drug Administration and the European Medicines
Agency accept adaptive designs but have issued guid-
ance on aspects that require special consideration
[2, 3]. However, oncology is the only area where adap-
tive designs are established [4, 5], and there is a relative
paucity of their use across other fields of medicine, in-
cluding rheumatology.
An adaptive design trial is one in which modifications
are made at various time points, dependent on pre-
specified outcomes collated from the data observed up
to that point. The modifications, time points [or more of-
ten, a point after which n patients have been recruited
or have sufficient outcome(s) data] and the outcomes
are many and variable, even within specific disease
areas. Modifications can include adaptations to the
randomization schedule, sample size re-estimation (both
blinded and unblinded) and changes to the inclusion/ex-
clusion criteria and to the mix of drugs defined as the in-
tervention. The various and multiple interim analyses in
these designs can allow for early curtailment of the trial
owing to futility, safety or non-inferiority, and certain
designs allow for intervention arms (such as multi-arm,
multi-stage [6]) to be dropped for these reasons. Other
designs allow for an operationally seamless transition
from phase II(a/b) to phase III [7]. These designs are far
removed from trials with incorporated interim analyses,
which are often less statistically rigorous [8].
Since their introduction, researchers have formulated
increasingly inventive designs to bring about the desired
purposes for undertaking these trials: flexibility, effi-
ciency and value for money (ever more pertinent in the
current political and economic global and academic cli-
mates). It is most important, however, to reduce any
possible harm to patients by attempting to minimize the
expected sample size required to prove (or otherwise)
the hypothesis in question.
The methodology for these designs started with
Gehan’s 1961 [9] single-arm design, Fleming’s [10] sin-
gle-stage design of 1982, then Simon’s [11] two-stage
design of 1989, with the notion of dual outcomes, for
both efficiency and toxicity, introduced by Bryant and
Day in 1995 [12]. Now we look to UK-based names,
such as Royston et al. [13], Burnett et al. and Hills and
Burnett [14, 15], Mander et al. and Wason and Mander
[16, 17], and Magirr et al. [18]. In the USA, luminaries in-
clude Thall and Cook [19], who introduced the concept
of Bayesian-adaptive designs, and Berry et al. [20], who
have furthered that field, in addition to O’Quigley et al.
[21].
Outcome Measures in Rheumatology (OMERACT) has
established a virtual special interest group to examine
how adaptive designs might be applied to rheumatology
research, in particular addressing issues set out in the
US Food and Drug Administration and European
Medicines Agency guidance [2, 3]. We focus on early
phase trials, because the US Food and Drug
Administration and European Medicines Agency have
accepted adaptive designs for early phase trials, but not
for phase III trials. Therefore, the purpose of this
systematic review was, first, to discover those early
phase trials that have used adaptive designs in RA, and
second, to describe the characteristics of early phase
trials to determine the benchmark, which the efficiency
of early phase trials using an adaptive design needs to
exceed. The results from this study will form the evi-
dence base that will underpin work of the OMERACT
Adaptive Clinical Trial Design Special Interest Group, by
providing the requirements for designing an early phase
trial in RA on matters such as the number of arms, the
number of patients, the primary outcome and when it is
measured. To implement an adaptive design into any
such trial, it will need to be shown that it can be supe-
rior in efficiency to the benchmark.
Methods
Search and eligibility criteria
The initial step for this systematic review was to search
for journal articles reporting the results of early phase tri-
als in rheumatology. This was undertaken in January
2015 using the OVID online database using the following
search terms:
((rheu* OR arth*) AND (early phase or phase 1 or phase I
or phase 2 or phase 2a or phase 2 b or phase II or
phase IIa or phase IIb) AND trial).ti.
The search included no specific terms for adaptive
designs, because the relevant articles should also be
identifiable as early phase trials under the terms used.
This search also included papers on PsA, OA and sys-
temic JIA, but these were later removed because the
objective of this systematic review focused on RA as a
specific exemplar. Ethical approval was not obtained to
undertake this systematic review, because it was not
required.
Data collection
Data were collected on phase, randomization, blinding,
whether the trial used an adaptive design (and, if so,
what sort), time period for data collection, countries in-
volved, amount of participation time, inclusion and ex-
clusion criteria, the intervention(s) and the treatment
schedules for control and intervention groups, the
primary outcome, when the primary outcome was
assessed, the total number, the number of arms and
number in each arm, and any additional outcomes, plus
any further notes. Results relating to the primary out-
come were also collected and were summarized using
forest plots created by RevMan5.3 [22] (with specific pri-
mary outcomes at specific time points grouped
together).
When the point at which the primary outcome was
assessed was not entirely clear, we applied the follow-
ing strategy: where adverse events were the primary
outcome, the amount of participation time was used;
where multiple outcomes were listed, the worst case
(longest duration) was taken.
Tim Pickles et al.
2 https://academic.oup.com/rheumap
D
ow
nloaded from
 https://academ
ic.oup.com
/rheum
ap/article-abstract/2/2/rky045/5133615 by Acquisitions user on 05 February 2019
Results
Based on abstracts, 35 papers were found in the OVID
search, of which nine papers were excluded
(supplementary Table S1, available at Rheumatology
Advances in Practice online) [23–31]. Eleven papers
were found through further manual searches, and 19
more came from searching the reference lists of papers
already found for review, or to be used in the discus-
sion. This gave a total of 56 papers (see supplementary
material extracted data, available at Rheumatology
Advances in Practice online) [32–87]. This information,
and that relating to how, and which, papers came to be
reviewed here is available is Fig. 1.
In 54 of these papers, a single trial was reported, ex-
cept for Choy et al. [35], in which three separate trials
are reported, and for Namour et al. [64], in which 5 sep-
arate trials are reported. Thus, there are 56 papers
reporting on 62 trials. Therefore, for each analysis, it is
noted whether it is referring to the number of papers or
the number of trials.
There was one example of an early phase trial using
an adaptive design in the 62 trials, which was part A of
Choy et al. [35].
The trials took place in a variety of different geograph-
ical regions, as shown in Table 1; the most common
was the USA. Phases were listed as I, Ib, II, IIa, IIb, I/II
and IIa/b, with phase II being the most frequent
(supplementary Table S2, available at Rheumatology
Advances in Practice online). All but five (plus a protocol
that was combined with another to form a trial [68])
used randomization. Of the 62 trials, 49 were double-
blinded, one was single-blinded (within Choy et al. [35]),
seven were open-label and one used the term ‘masked’
[57]. The length of overall data collection time (from 20
of 56 papers) ranged from 3 to 61 months, with a mean
of 19.9 (S.D.: 12.84) months and a median of 16.5 [inter-
quartile range (IQR): 13.0; 23.5] months. The amount of
trial participation time ranged from 0.86 to 76 weeks (from
61 of 62 trials), with a mean of 18.5 (S.D.: 13.77) weeks
and a median of 16.0 (IQR: 9.0; 24.0) weeks.
Numerous inclusion and exclusion criteria were ap-
plied across these papers (see supplementary material,
available at Rheumatology Advances in Practice online).
The main areas were for inclusion were as follows: ful-
filled ACR [88] criteria; DAS28 [89], CRP, ESR and/or
morning stiffness above specified values; number of
swollen and tender joints above a specified value; failed
previous DMARD treatment; length and stability of MTX
treatment; and, age, generally >18 years, and some-
times limited to a maximum of 75 years. For exclusion,
these were as follows: recent DMARD treatment; and
stability of NSAID treatment.
Of the 62 trials, 14 did not include a control arm.
Forty-six used some form of placebo, although two
[53, 54] used background MTX throughout all arms in
combination with placebo or the study treatment.
The most common primary outcome was ACR20 [90]
(Table 2), with many secondary outcomes measured
(usually reflecting the RA core set) [91]. The full list is
available in the supplementary material, available at
Rheumatology Advances in Practice online, but the most
frequent were the individual components of DAS28 [89]
and the ACR 50 and 70 response criteria.
The time at which the primary outcome was measured
ranged from 2 to 26 weeks (from 37 of 62 trials), with a
mean of 13.6 (S.D.: 7.32) weeks and a median 12.0 (IQR:
9.0; 20.0) weeks.
The total number of patients ranged from 12 to 509
(from all 62 trials), with a mean of 133.8 (S.D.: 132.55)
and a median of 73.0 (IQR: 35.3; 222.5). The number of
arms ranged from 2 to 9 (from all 62 trials), with a mean
of 4.3 (S.D.: 2.06) and a median of 4.0 (IQR: 2.8; 6.0).
The number of patients per arm ranged from 3.13 to
FIG. 1 Flow of numbers of papers (and numbers of trials described) throughout the different search phases
Early phase trials in RA
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252.00 (from all 62 trials), with a mean of 34.01 (S.D.:
39.041) and a median of 23.42 (IQR: 8.44; 51.46).
The forest plots (Figs 2 and 3) show that the odds ra-
tios and effect sizes found in these papers are highly
varied, but these results are either positive or indicate
null findings (i.e. no evidence of a difference). There are
no published negative results available.
Discussion
There are many key issues that should be addressed for
adaptive design trials before use for the rheumatic dis-
eases (Table 3). There was only one example of an early
phase trial using an adaptive design in the 62 trials,
which was part A of Choy et al. [35]. From the papers
reviewed here, the benchmark early phase trial in RA is
a phase II double-blinded randomized trial, with four
arms (one control and three intervention) containing
134 patients (34 in each arm), and a primary outcome
of ACR20 [90] measured at 16 weeks. (The mean points
to 13.6 weeks, but given that measurements are gener-
ally taken every 4 weeks, this rounds up to 16 weeks). It
should be noted, however, that this is a very general set
of values taken from widely varying research, some of
which was inherently biased to have certain criteria by
the very nature of the interaction between the interven-
tion and the population sampled.
It appears that the standard is to use composite
measures, such as ACR20 [90] or DAS28 [89], measured
at a time point of 16 weeks. For adaptive designs to be
implemented properly in this field and to provide the
improvements in efficiency desired, we require a highly
discriminate outcome measure, which can be assessed
at early time points for interim analyses implemented in
these designs. Analysing the response characteristic of
commonly used outcome measures over time will be vi-
tal. Given the small sample, missing data imputation
might also have an important role.
A paper found in the search but not reviewed, in that
it was a simulation study, was by Thygesen et al. [27].
Here, the authors undertook a set of simulations around
TABLE 1 Countries in which early phase clinical trials in RA are taking place (data from 39 of 56 papers)
Country n
USA 15
The Netherlands 11
UK 9
Belgium 8
Germany 7
Russia 5
Canada, Norway, Poland, Serbia/(former state of) Serbia and Montenegro 4
Austria, Australia, Finland, Hungary, Ukraine 3
Brazil, China, Czech Republic, Denmark, Japan, Mexico, New Zealand, Romania, Spain, Sweden 2
Argentina, Belarus, Chile, Colombia, Egypt, Estonia, France, Georgia, Greece, India, Israel, Italy, Lithuania, Malaysia,
Philippines, Portugal, Republic of Korea, Slovakia, South Africa, Switzerland, Taiwan, Thailand, Turkey
1
TABLE 2 Primary outcomes (data from 37 of 62 trials)
Outcome n (%)
ACR20 18 (48.6)
DAS28 6 (16.2)
Adverse events 2 (5.4)
Area under curve formed from ACR20 at three time points 1 (2.7)
ACR20 þ ACR50 1 (2.7)
CRP þ ESR 1 (2.7)
Efficacy (based on clinical symptoms, signs and laboratory tests; <30% is ineffective,
30% to <50% is effective, and 50% is remarkable)
1 (2.7)
Modified Paulus approach 1 (2.7)
MRI erosion score 1 (2.7)
Paulus20 1 (2.7)
Radiological score (Van der Heijde modified Sharp score) 1 (2.7)
SJC 1 (2.7)
Time exhibiting Paulus20, weeks 1 (2.7)
TJC þ SJC 1 (2.7)
SJC: swollen joint count; TJC: tender joint count.
Tim Pickles et al.
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a Bayesian dose-finding procedure applied to an adap-
tive seamless phase I/II trial, specifically in RA. This was
a bivariate procedure to look at both safety and efficacy,
and the set-up was thus that the hypothetical trial
collected data on these when the patient received the
treatment every 4 weeks. For safety, information on all
adverse events was collected, and if any of these
matched a pre-defined list, the event was considered a
FIG. 2 Forest plot of dichotomous outcomes (ACR20, ACR50, modified Paulus approach, Paulus20 and 50% de-
crease in swollen joint count from baseline)
mPa: Paulus approach (see supplementary material, available at Rheumatology Advances in Practice online for detail);
P20: Paulus20; SJC50: 50% decrease in swollen joint count from baseline. Numbers in brackets are [Search
Number].[Intervention Number], as noted in the supplementary material, available at Rheumatology Advances in
Practice online.
Early phase trials in RA
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dose-limiting event. For efficacy, CRP and ACR20 were
also recorded. The outcomes were thus:
(i) Occurrence of a dose limiting event within 4 weeks of treatment
(yes or no)—a measure of safety; (ii) Success with respect to
ACR20 at 4 weeks and a 25% reduction in CRP at 4 weeks relative
to baseline (yes or no)—an early indicator of efficacy; (iii) Success
with respect to ACR20 at 16 weeks (yes or no)—a more reliable in-
dicator of efficacy [27].
This suggests that it is possible to look at outcomes,
such as CRP and ACR20, at a relatively early time point.
Equally, in part A of Choy et al. [35], we see that the pri-
mary outcome was the change in DAS28 from baseline
to day 14. At this point, and having been measured every
week, the safety, tolerability, efficacy, pharmacokinetics
and pharmacodynamics were assessed. Also, in a paper
[40] using the Paulus20 outcome [92], efficacy was
assessed at week 4. However, in the majority of the
papers reviewed here, it seems that researchers are
rarely keen to use ACR20 or DAS28 outcomes at a time
point that would be suitable for an adaptive design. Vital
research is required to investigate early, potentially
patient-reported, outcomes that are predictive of even-
tual ACR20 or DAS28 results so that sample size and
trial design may be adjusted.
It is also important that both papers show that these
designs do not require large numbers in comparison
with the benchmark trial we have reported with 134
patients. Part A of Choy et al. [35] required 64 patients,
FIG. 3 Forest plot of continuous outcomes (DAS28)
Number in brackets are [Search Number].[Intervention Number], as noted in the supplementary material, available at
Rheumatology Advances in Practice online.
TABLE 3 Methodological issues with adaptive design trials in rheumatology
Methodological
issues
Dissemination of interim results, especially if not fully blinded or incorporate some subjective element/analyst
access to unblinded interim results and how they may influence investigators managing the trial (who must
remain unequivocally objective), i.e. operational bias
Decision-making around early stopping should not be based solely on a statistically significant primary
analysis, but should also include results of subgroup analyses and careful assessment of the adequacy of
the safety database
Whether patients who have yet to reach the interim time point should be included in these analyses or not,
especially if this influences the potential decision-making
Results based on P-values alone
Control of the type I error rate
Interpretation of study results when the study design has changed as a result of interim analyses
Rejection of a global null hypothesis across all stages, which may not be sufficient or methodologically
sound
Involvement of sponsor personnel in interim decision-making
Differential population for recruitment before and after modification, which will affect treatment effect
Making hypothesis claims from results of interim analyses
Interim analyses/adaptation choices provide multiple opportunities to show a successful treatment effect
(with greater likelihood of doing so than if no such analyses existed), thus introducing inherent multiplicity
bias
The potential to select a modification as a result of an interim analysis that, by random chance, is more
favourable than the true value, thus creating bias that will lead to an overestimate of the true treatment
effect
Limiting the opportunity to reflect on the data, including safety issues, and thus limiting the design of future
well-thought-through research
An increase in pressure to make assumptions, even when only limited prior information exists
Exploratory adaptive design study flaws, which could lead to sub-therapeutic dose selection in subsequent
(adequate and well-controlled) trials
Tim Pickles et al.
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and the various simulations of Thygesen et al. [27] re-
quired numbers as low as 74. Although there is not
enough evidence here to say for certain, this is indica-
tive of the notion that adaptive designs tend to require
fewer patients than standard trial designs.
Another relevant factor here is the overly restrictive in-
clusion and exclusion criteria, which makes for highly
stringent recruitment barriers. This then drives up the
length of time required for data collection, which was al-
most 2 years on average. To collect data on only 134
patients in this time shows that the throughput of
patients into these trials is simply too slow.
It is also worth noting that all the papers reviewed
here provided only positive or no-evidence-of-a-
difference results (Figs 2 and 3), which, along with the
fact that most of this research is done in the private
sector, explains the small number of papers available.
Publication bias based on the main trial outcome [93]
has already been shown to be a disappointing barrier to
furthering rheumatological research, which undoubtedly
means that time, money and other resources are wasted
on research that is already known to be fruitless.
In addition to the methodological papers laid out in
the Introduction [9–21], there are numerous examples of
adaptive designs in practice in the field of oncology,
many of which are summarized in reviews [5, 94]. These
have mostly made use of group sequential methods [95,
96]. Part A of Choy et al. [35], was a randomized,
double-blind placebo-controlled Bayesian-adaptive
dose-finding study. This used trial simulations of the
Bayesian-adaptive pharmacokinetic/pharmacodynamic
design to estimate the sample size and a Bayesian-
adaptive dose-finding algorithm to identify subsequent
doses after the starting dose [97].
In a 2015 editorial in The Journal of Rheumatology,
Pope et al. [1] wrote:
Over the last 2 decades, we have seen advances in the clinical
management of rheumatoid arthritis, psoriatic arthritis, ankylosing
spondylitis, systemic sclerosis, vasculitis, and systemic lupus ery-
thematosus. Yet trial designs and entry criteria required for drug
development have not kept pace with medical care and thus no
longer reflect patients seen in typical rheumatology practices in
Canada, the United States and Western Europe [1].
In addition to this editorial, the Canadian Rheumatology
Research Consortium has also suggested changes [98],
which focus on both inclusion and exclusion criteria and
study design.
We already know that updates can be made in the
field of rheumatology. Five years before his paper defin-
ing the ACR20, 50 and 70 outcomes [90], Felson et al.
[99] had published on the need for standardized out-
comes and reporting. Also, a review in 2009 [100]
showed how far trial design for RA had advanced in the
previous decade, which noted the already existing de-
bate [101, 102]. We are therefore hopeful that research-
ers in rheumatology and clinical trialists can start a
change of the tide. The key objectives of the OMERACT
Adaptive Clinical Trial Design Virtual Special Interest
Group are to identify and address key barriers to
adaptive design for clinical trials in RA and to improve
clinical efficiency, which will benefit patients, researchers
and funders.
Conclusion
Our search discovered a single example of an early
phase trial that used an adaptive design in RA. We have
described the benchmark, which the efficiency of early
phase trials using an adaptive design needs to exceed.
Research into treatments for RA should make use of
adaptive designs if there is a desire to move forward in
the world, or else it will begin to lag behind other clinical
research efforts [5]. Beyond the academic elegance and
need for statistical a priori definitions, these designs can
reduce numbers in terms of participants and resources
and can lead to trials that are operationally connected.
Whether we create, test and use objective early-time-
point outcomes for use in adaptive designs may well be
the important question. We must look for innovative
ways of measuring outcomes in RA at much earlier time
points. Also, we would need to look at which of these
outcomes is more discriminatory.
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